{"id":"infacort","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infacort delivers hydrocortisone in a biphasic release pattern that approximates the body's natural cortisol curve, with higher levels in the early morning and lower levels in the evening. This circadian-aligned dosing aims to reduce glucocorticoid-related adverse effects while maintaining adequate cortisol replacement throughout the day. The modified-release formulation allows for once-daily dosing compared to multiple daily doses of conventional hydrocortisone.","oneSentence":"Infacort is a modified-release hydrocortisone formulation designed to mimic the natural circadian rhythm of cortisol secretion in patients with adrenal insufficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:59.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adrenal insufficiency (primary, secondary, and tertiary)"}]},"trialDetails":[{"nctId":"NCT02720952","phase":"PHASE3","title":"Treatment of Adrenal Insufficiency in Children","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2015-03","conditions":"Adrenal Insufficiency","enrollment":24},{"nctId":"NCT01960530","phase":"PHASE1","title":"An Investigational Study of Hydrocortisone","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2013-10","conditions":"Adrenal Insufficiency","enrollment":14},{"nctId":"NCT02733367","phase":"PHASE3","title":"Extension Study for Patients Entered Into Study Infacort 003","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-03-04","conditions":"Adrenal Insufficiency","enrollment":18},{"nctId":"NCT03311932","phase":"PHASE1","title":"A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2018-04-16","conditions":"Adrenal Insufficiency","enrollment":51},{"nctId":"NCT02777268","phase":"PHASE1","title":"Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2013-07","conditions":"Healthy Subjects","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Infacort®","genericName":"Infacort®","companyName":"Neurocrine UK Limited","companyId":"neurocrine-uk-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infacort is a modified-release hydrocortisone formulation designed to mimic the natural circadian rhythm of cortisol secretion in patients with adrenal insufficiency. Used for Adrenal insufficiency (primary, secondary, and tertiary).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}